Physician profile
Peter Dellatore
NPI 1851829725
$3,106.52
in general payments reported to CMS, 2019-2025
26 companies · $1,398 in 2025
The $1,398 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $359 · 2024: $1,350 · 2025: $1,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,073 · Education: $33.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,072.71 |
| Education | $33.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $920.20 | 2023-2025 | Skyrizi, Rinvoq, Linzess |
| Madrigal Pharmaceuticals | $318.55 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $263.62 | 2023-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $238.01 | 2023-2025 | |
| Pfizer INC. | $188.98 | 2023-2025 | |
| Janssen Biotech, INC. | $172.14 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $142.18 | 2023-2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $133.84 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $125.73 | 2025 | Ibsrela |
| Lilly USA, LLC | $102.37 | 2024-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.78 | 2024-2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $63.55 | 2023-2025 | Vowst, Zenpep |
| Ipsen Biopharmaceuticals, INC | $59.33 | 2024-2025 | Iqirvo, Bylvay |
| Laborie Medical Technologies Corp. | $40.41 | 2024 | |
| Celltrion USA INC. | $33.81 | 2024 | Zymfentra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $31.40 | 2023-2024 | Rebyota |
| Novo Nordisk INC | $31.38 | 2023-2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $31.32 | 2025 | |
| Ironwood Pharmaceuticals, INC | $20.29 | 2024 | |
| Blueprint Medicines Corporation | $19.61 | 2023 | |
| Merck Sharp & Dohme LLC | $18.69 | 2024 | Dificid |
| Braintree Laboratories, INC. | $17.98 | 2025 | Sutab, Suflave |
| Dynavax Technologies Corporation | $15.49 | 2025 | Heplisav-B |
| Exact Sciences Corporation | $14.81 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.71 | 2023 | Cyltezo |
| Celgene Corporation | $13.34 | 2024 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Dellatore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.